From Medscape Neurology

Coverage from the

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016

February 18 - 20, 2016; New Orleans, Louisiana

February 18 - 20, 2016 New Orleans, Louisiana
  • ACTRIMS Biomarkers May Predict Progression in MS Researchers have identified a proinflammatory profile in CSF that may correlate with cortical pathology and could prove useful to stratify patients with early progressive multiple sclerosis.
  • ACTRIMS Ocrelizumab Benefit Consistent in Progressive MS Subgroup analysis of the phase 3 ORATORIO trial found patients with T1 Gd-positive and Gd-negative lesions experienced benefits in line with those of the whole study population after treatment with ocrelizumab.
  • ACTRIMS Disease Suppression Persists With Ozanimod at 72 Weeks in MS The 48-week extension of the RADIANCE trial showed persistent benefit for ozanimod, reduced gadolinium-enhancing lesions, and a low relapse rate.

Conference News

Recent Medscape News on Multiple Sclerosis

Medscape Neurology©  WebMD, LLC